Analysts think CYTK stock price could increase by 36%
Sep 07, 2025, 11:25 AM
7.24%
What does CYTK do
Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
21 analysts think CYTK stock price will increase by 36.46%. The current median analyst target is $72.42 compared to a current stock price of $53.07. The lowest analysts target is $41.41 and the highest analyst target is $126.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
